Skip to main content

Animations

Illustrated close up of DNA.

Research Tools Catalog

To save researchers time and resources, The Michael J. Fox Foundation has made a number of tools available to the scientific community at low cost, with rapid delivery.

Helpful Resources

  • Illustrated adjacent hexagons.

    Sponsored Tools Program

    Learn more about how MJFF can help share your tools.

  • Illustrated Parkinson's Disease Research Tools Consortium logo.

    Tools Consortium

    MJFF is working with industry to develop priority tools.

  • Illustrated brain on a presentation display.

    Preclinical Models

    Learn more about the various in vivo models used in Parkinson's disease research.

Find a Research Tool

Filter by Tool Type or Gene/Protein Type to Organize Results

* = MJFF does not control pricing or terms of availability for this tool. 

Filters
Sort options
Sort by
Order
Filters
Sort options
Sort by
Order
Sort options
Sort by
Order
Results (357)
Sort by:
ITPKB Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered homozygous knockout of ITPKB. These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by the Aligning Science Across Parkinson’s (ASAP) Initiative. Estimated Availability: Late 2026
  • ITPKB
GALC Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in GALC, including heterozygous and homozygous R101X, heterozygous and homozygous Y541S, and homozygous knockout mutations. These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by the Aligning Science Across Parkinson’s (ASAP) Initiative. Estimated Availability: Late 2025 
  • GALC
Rab21 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in Rab21, including
  • -S71R (heterozygous and homozygous) - in development, estimated late 2026
  • -Knockout (homozygous) - in development, estimated late 2026
These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by the Aligning Science Across Parkinson’s (ASAP) Initiative.  
  • Rab
RAB32 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in RAB32, including 
  • -S71R (heterozygous and homozygous) - in development, est late 2025
  • -Knockout (homozygous) - in development, est late 2025
These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by the Aligning Science Across Parkinson’s (ASAP) Initiative
  • Rab
SCARB2 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in SCARB2, including
  • -R424* (heterozygous and homozygous) - in development, est late 2025
  • -W146Sfs*15 (heterozygous and homozygous) - in development, est late 2025
  • -Knockout (homozygous) - in development, est late 2025
These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by the Aligning Science Across Parkinson’s (ASAP) Initiative
  • SCARB2
Parkin Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in PRKN, including 
  • -R42P (heterozygous and homozygous)
  • -T240M (heterozygous and homozygous)
  • -R275W (heterozygous and homozygous)
  • -P437L (heterozygous and homozygous)
These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by the Aligning Science Across Parkinson’s (ASAP) Initiative
  • PRKN
DJ-1 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in PARK7 (DJ-1), including:
  • -D194A (heterozygous and homozygous)
  • -L166P(heterozygous and homozygous)
These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by the Aligning Science Across Parkinson’s (ASAP) Initiative
  • DJ-1
SPTSSB Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered homozygous knockout of SPTSSB.These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by the Aligning Science Across Parkinson’s (ASAP) Initiative. Estimated Availability: Late 2026 
  • SPTSSB
STING1 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered heterozygous and homozygous knockout of STING1.  These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD). This cell line development project is part of the MJFF Targets to Therapies (T2T) Initiative. Estimated Availability: Late 2026 
  • STING1
TLR2 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered heterozygous and homozygous knockout of TLR2.These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD).This cell line development project is part of the MJFF Targets to Therapies (T2T) Initiative. Estimated availability: late 2026
  • TLR2
Have questions or need additional information?

Email tools@michaeljfox.org with questions and to suggest new tools for us to develop. Or visit our FAQ page. 

"We have shown, thanks in part to MJFF, that researchers now have in their pantry the right ‘ingredients’, to... help to drive forward PD drug development.”
Heather Melrose, PhD Mayo Clinic
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.